SNDX — Syndax Pharmaceuticals, Inc. stock price, charts and financials
QT67Syndax Pharmaceuticals, Inc.Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
19.24
+0.19+1.00%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -2.80 | Insider Own | 5.62% | Shs Outstand | 88.61M | Perf Week | -8.46% |
| Market Cap | 1.69B | Forward P/E | - | EPS next Y | -0.47 | Insider Trans | -2.73% | Shs Float | 79.61M | Perf Month | -8.81% |
| Enterprise Value | 1.90B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 26.15% | Perf Quarter | -11.11% |
| Income | -248.81M | P/S | 7.77 | EPS this Y | 40.48% | Inst Trans | - | Short Ratio | 10.64 | Perf Half Y | -7.48% |
| Sales | 217.17M | P/B | 39.65 | EPS next Y | 71.89% | ROA | -51.46% | Short Interest | 20.82M | Perf YTD | -9.33% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -256.66% | 52W High | 25.85 -25.56% | Perf Year | 90.69% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -57.76% | 52W Low | 9.58 100.74% | Perf 3Y | -11.93% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - 143.72% | Gross Margin | 97.96% | Volatility | 4.89% 5.14% | Perf 5Y | 33.59% |
| Dividend TTM | - | EV/Sales | 8.76 | EPS Y/Y TTM | 24.93% | Oper. Margin | -102.93% | ATR (14) | 1.06 | Perf 10Y | 56.92% |
| Dividend Ex-Date | - | Quick Ratio | 5.06 | Sales Y/Y TTM | 804.17% | Profit Margin | -112.01% | RSI (14) | 35.90 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.47 | EPS Q/Q | 51.02% | SMA20 | -13.66% | Beta | 0.39 | Target Price | 38.50 |
| Payout | 0.00% | Debt/Eq | 8.30 | Sales Q/Q | 225.00% | SMA50 | -6.69% | Rel Volume | 0.64 | Prev Close | 19.05 |
| Employees | 298 | LT Debt/Eq | 5.32 | Earnings | Aug 04 | SMA200 | -6.43% | Avg Volume | 1.89M | Price | 19.24 |
| IPO Date | Mar 02, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 21.02% -7.02% | Net Debt/EBITDA | -1.32 | Volume | 1,205,672 | Change | 1.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-12-26 | Reiterated | Guggenheim | Buy | $34 → $31 |
| Jun-03-26 | Reiterated | H.C. Wainwright | Buy | $33 → $40 |
| May-04-26 | Reiterated | Stifel Nicolaus | $45 → $46 | |
| May-01-26 | Reiterated | Barclays | Overweight | $35 → $37 |
| Feb-27-26 | Reiterated | Stifel Nicolaus | $44 → $45 | |
| Nov-24-25 | Reiterated | Barclays | Overweight | $22 → $35 |
| Nov-04-25 | Reiterated | Barclays | Overweight | $33 → $22 |
| Nov-04-25 | Reiterated | UBS | Buy | $35 → $38 |
| Sep-10-25 | Resumed | Stifel | Buy | $44 |
| Jul-15-25 | Reiterated | UBS | Buy | $37 → $35 |
Latest News
Jul-28-26
Jul-28-2607:00AM
Jul-17-26
Jul-17-2601:01PM
Jul-15-26
Jul-15-2606:29AM
04:11AM
Jul-14-26
Jul-14-2604:03PM
10:56AM
08:00AM
Jul-08-26
Jul-01-26
Jul-01-2604:01PM
Jun-26-26
Jun-12-26
Jun-12-2608:16AM
Jun-11-26
Jun-11-2608:57AM
07:11AM
Jun-10-26
Jun-10-2601:12PM
Company
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 217 | 172 | 24 | 0 | 0 | 140 | 2 | 2 | 2 | |
| Cost of Goods Sold Incl. D&A | 4 | 7 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 213 | 165 | 23 | 0 | 0 | 140 | 2 | 2 | 2 | |
| Selling, General and Administrative Excl. Other | 177 | 180 | 121 | 67 | 33 | 25 | 23 | 16 | 17 | |
| Research and Development | 256 | 259 | 242 | 163 | 118 | 88 | 50 | 43 | 60 | |
| Other Operating Expense | 3 | -1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Operating Income | -223 | -273 | -340 | -230 | -152 | 26 | -71 | -58 | -76 | |
| Interest Expense | 81 | 34 | 5 | 0 | 3 | 2 | 2 | 0 | 2 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 60 | 21 | 26 | 21 | 6 | 1 | 1 | 1 | 4 | |
| Net Income Before Taxes | -244 | -285 | -319 | -209 | -149 | 25 | -73 | -56 | -74 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -244 | -285 | -319 | -209 | -149 | 25 | -73 | -56 | -74 | |
| Net Income From Continuing Operations | -244 | -285 | -319 | -209 | -149 | 25 | -73 | -56 | -74 | |
| Net Income | -244 | -285 | -319 | -209 | -149 | 25 | -73 | -56 | -74 | |
| EPS (Recurring) | -2.80 | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 | -1.84 | -2.92 | |
| EPS (Basic, Before Extraordinaries) | -2.80 | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 | -1.84 | -2.92 | |
| EPS (Diluted) | -2.80 | -3.29 | -3.73 | -2.98 | -2.46 | 0.48 | -1.77 | -1.84 | -2.92 | |
| EBITDA | -162 | -252 | -314 | -209 | -146 | 27 | -70 | -56 | -74 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | 45.60 | — | — | — | |
| Price To Sales Ratio | 7.71 | 10.63 | 47.37 | — | — | 8.13 | 455.92 | 131.70 | 55.63 | |
| Gross Margin | 98.16 | 95.93 | 95.83 | — | — | 100.00 | 100.00 | 100.00 | 100.00 | |
| Operating Margin | -102.76 | -158.72 | -1,416.67 | — | — | 18.57 | -3,550.00 | -2,900.00 | -3,800.00 | |
| Net Margin | -112.44 | -165.70 | -1,329.17 | — | — | 17.86 | -3,650.00 | -2,800.00 | -3,700.00 | |
| Shares Outstanding | 87 | 87 | 86 | 70 | 61 | 52 | 41 | 30 | 25 | |
| Market Capitalization | 1,674 | 1,828 | 1,137 | 1,513 | 1,552 | 1,138 | 912 | 263 | 111 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | Jul 08 '26 | Sale | 24.24 | 32,375 | 784,776 | 484,843 | Jul 09 |
| Metzger Michael A | Chief Executive Officer | Jul 08 '26 | Option Exercise | 6.38 | 64,750 | 413,106 | 517,218 | Jul 09 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Jun 12 '26 | Option Exercise | 13.82 | 62,470 | 863,336 | 92,120 | Jun 12 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Jun 12 '26 | Sale | 18.14 | 31,235 | 566,603 | 60,885 | Jun 12 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Jun 11 '26 | Sale | 18.00 | 34,280 | 617,040 | 60,885 | Jun 12 |
| Botwood Nicholas A.J. | Head of R&D, CMO | Jun 11 '26 | Option Exercise | 13.82 | 22,515 | 311,157 | 95,165 | Jun 12 |
| Goldan Keith A. | Chief Financial Officer | Jun 01 '26 | Sale | 18.99 | 1,177 | 22,351 | 139,252 | Jun 02 |
| Metzger Michael A | Chief Executive Officer | Jun 01 '26 | Sale | 18.99 | 6,847 | 130,025 | 484,843 | Jun 02 |
| Metzger Michael A | Chief Executive Officer | Feb 09 '26 | Sale | 21.03 | 17,159 | 360,819 | 491,690 | Feb 10 |
| Goldan Keith A. | Chief Financial Officer | Feb 09 '26 | Sale | 21.03 | 3,410 | 71,705 | 140,429 | Feb 10 |
| Goldan Keith A. | Chief Financial Officer | Feb 06 '26 | Sale | 20.62 | 2,082 | 42,931 | 143,839 | Feb 06 |
| Metzger Michael A | Chief Executive Officer | Feb 06 '26 | Sale | 20.62 | 7,412 | 152,835 | 508,849 | Feb 06 |
| Metzger Michael A | Chief Executive Officer | Sep 08 '25 | Sale | 16.41 | 157,307 | 2,582,021 | 298,661 | Sep 08 |
| Metzger Michael A | Chief Executive Officer | Sep 08 '25 | Option Exercise | 10.90 | 314,614 | 3,429,292 | 455,968 | Sep 08 |
| Podlesak Dennis | Director | Aug 18 '25 | Option Exercise | 7.20 | 19,200 | 138,240 | 210,963 | Aug 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.